A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Recruiting Phase 1 Interventional Study
Advanced / Metastatic Solid Tumor
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
25 (estimated)
Sponsor
Stingray Therapeutics · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Life expectancy of at least 3 months 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 3. Histopathologically/cytologically confirmed advanced solid tumor, which is refractory to standard therapeutic options, or for which there are no standard therapeutic …
Contacts

Sunil Sharma

602-343-8402

Sunil Sharma <ssharma@honorhealth.com>

CONTACT

Jonathan Northrup

317-517-9500

jon@stingraytx.com

CONTACT